NRG Therapeutics

NRG Therapeutics is a drug discovery company focused on restoring mitochondrial function and slowing or halting the progression of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and motor neuron disease. NRG possesses a series of brain-penetrant mitochondrial permeability transition pore (mPTP) small molecule inhibitors, which have the potential to become first-in-class treatments for Parkinson's disease (PD) and motor neuron disease (MND).